Journal of Pain and Symptom Management
Volume 23, Issue 5 , Pages 355-368 , May 2002

Dose Conversion and Titration with a Novel, Once-Daily, OROS® Osmotic Technology, Extended-Release Hydromorphone Formulation in the Treatment of Chronic Malignant or Nonmalignant Pain

  • Mark Palangio, MS

      Affiliations

    • Abbott Laboratories, Parsippany, NJ USA
    • Corresponding Author InformationAddress reprint requests to: Mark Palangio, MS, Abbott Laboratories, Morris Corporate Center I, 300 Interpace Parkway, Parsippany, NJ 07054, USA
    • ,
  • Donald W Northfelt, MD, MS, FACP

      Affiliations

    • Department of Medicine, University of California School of Medicine, San Diego, CA USA
    • ,
  • Russell K Portenoy, MD

      Affiliations

    • Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY USA
    • ,
  • Daniel Brookoff, MD, PhD

      Affiliations

    • Department of Internal Medicine, University of Tennessee College of Medicine, Memphis, TN, USA
    • ,
  • Ralph T Doyle Jr., BA

      Affiliations

    • Abbott Laboratories, Parsippany, NJ USA
    • ,
  • Bruce E Dornseif, PhD

      Affiliations

    • Abbott Laboratories, Parsippany, NJ USA
    • ,
  • Michael C Damask, MD

      Affiliations

    • Abbott Laboratories, Parsippany, NJ USA

,Accepted 8 August 2001.

References 

  1. Reisine T, Pasternak G. Opioid analgesics and antagonists. In:  Hardman JG,  Limbird LE editor. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 1996;p. 521–555
  2. Sarhill N, Walsh D, Nelson KA. Hydromorphone (pharmacology and clinical applications in cancer patients). Support Care Cancer. 2001;9:84–96
  3. Houde RW. Clinical analgesic studies of hydromorphone. In:  Foley KM,  Intrussi CE editor. Advances in pain research and therapy. New York: Raven Press; 1986;p. 129–141
  4. Storey P, Hill HH, St Louis RH, Tarver EE. Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manage. 1990;5:33–41
  5. Bruera E, Pereira J, Watanabe S, et al.  Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;15;78:852–857
  6. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain (a retrospective study). Pain. 1997;72:79–85
  7. Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981;21:152–156
  8. Ferrell B, Wisdom C, Wenzl C, Brown J. Effects of controlled-released morphine on quality of life for cancer pain. Oncol Nurs Forum. 1989;16:521–526
  9. Shah J, Gupta S, Singh S, Peng J. Multiple dose pharmacokinetics of OROS® and immediate release (IR) hydromorphone (HM) in healthy subjects (abstract). Pharm Res. 1997;14:617;S–
  10. Drover DR, Angst MS, Naidu S, Ramaswamy B. The pharmacokinetics of hydromorphone SR (abstract). Anesthesiol. 1999;91(3A supplement):
  11. Angst MS, Drover DR, Lotsch J, et al.  Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiol. 2001;94:63–73
  12. Hays H, Hagen N, Thirlwell M, et al.  Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer. 1994;74:1808–1816
  13. Hagen N, Thirlwell MP, Dhaliwal HS, et al.  Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol. 1995;35:37–44
  14. Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer. 1997;79:1428–1437
  15. Bloomfield SS, Cissell GB, Mitchell J, et al.  Analgesic efficacy and potency of two oral controlled-release morphine preparations. Clin Pharmacol Ther. 1993;53:469–478
  16. Broomhead A, Kerr R, Tester W, et al.  Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage. 1997;14:63–73
  17. Citron ML, Kaplan R, Parris WC, et al.  Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. Cancer Invest. 1998;16:562–571
  18. Hussey EK, Donn KH, Powell JR. Albuterol extended-release products (a comparison of steady-state pharmacokinetics). Pharmacotherapy. 1991;11:131–135
  19. Berelowitz M, Fischette C, Cefalu W, et al.  Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care. 1994;17:1460–1464
  20. Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine. Am J Hypertens. 1995;8:87–89
  21. Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet. 1996;30:28–51
  22. Neutel JM, Alderman M, Anders RJ, Weber MA. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. Am Heart J. 1996;132:1202–1206
  23. Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther. 1999;21:634–642
  24. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS® (methylphenidate HCl) formulation. J Clin Pharmacol. 2000;40:379–388
  25. Storey P. More on the conversion of transdermal fentanyl to morphine (letter). J Pain Symptom Manage. 1995;10:581–582
  26. Daunt RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197–210
  27. American Pain Society . Principles of analgesic use in the treatment of acute and cancer pain. 4th edition. Glenview, Il: American Pain Society;; 1999;
  28. Deschamps M, Band PR, Hislop TG, et al.  The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine. J Pain Symptom Manage. 1992;7:384–392
  29. Salzman RT, Roberts MS, Wild J, et al.  Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control?. J Pain Symptom Manage. 1999;18:271–279
  30. Portenoy RK, Coyle N. Controversies in the long-term management of analgesic therapy in patients with advanced cancer. J Pain Symptom Manage. 1990;5:307–319
  31. Arkinstall W, Sandler A, Goughnour B, et al.  Efficacy of controlled-release codeine in chronic non-malignant pain (a randomized, placebo-controlled clinical trial). Pain. 1995;62:169–178
  32. Moulin DE, Iezzi A, Amireh R, et al.  Randomized trial of oral morphine for chronic non-cancer pain. Lancet. 1996;347:143–147
  33. Roth SH, Fleischmann RM, Burch FX, et al.  Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain (placebo-controlled trial and long-term evaluation). Arch Intern Med. 2000;160:853–860
  34. Peloso PM, Bellamy N, Bensen W, et al.  Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol. 2000;27:764–771
  35. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain (report of 38 cases). Pain. 1986;25:171–186
  36. Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage. 1992;7:69–77
  37. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain (new hypotheses derived from studies of opioid infusions). Pain. 1990;43:273–286
  38. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurol. 1991;41:1024–1028
  39. Watson CPN, Babul N. Placebo-controlled evaluation of the efficacy and safety of controlled release oxycodone in postherpetic neuralgia. Proceedings of 8th World Congress on Pain, Vancouver, British Columbia, Canada, August 17–22, 1996.

PII: S0885-3924(02)00390-1

Journal of Pain and Symptom Management
Volume 23, Issue 5 , Pages 355-368 , May 2002

Article Tools

* Image Usage & Resolution